Sign In
Buy CADL
$8.80
+0.380 (+4.51%)
At Close: Jun 03, 2026
Candel Therapeutics advances toward prostate cancer therapy filing after trial success
08:51am, Thursday, 14'th Aug 2025
Candel Therapeutics Inc (NASDAQ:CADL) said on Thursday it plans to seek US approval for its lead cancer drug CAN-2409 in late 2026, after a key Phase 3 prostate cancer trial succeeded and the FDA gran
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
08:05am, Thursday, 14'th Aug 2025
NEEDHAM, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
08:05am, Wednesday, 30'th Jul 2025
NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic
Candel Therapeutics receives EMA Orphan Designation for immunotherapy candidate CAN-2409
09:21am, Thursday, 24'th Jul 2025
Candel Therapeutics Inc (NASDAQ:CADL) announced that the European Medicines Agency (EMA) has granted Orphan Designation to its investigational immunotherapy CAN-2409 for the treatment of pancreatic ca
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer
08:05am, Thursday, 24'th Jul 2025
NEEDHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic
Candel Therapeutics expands Russell Index presence following 2025 reconstitution
09:09am, Wednesday, 09'th Jul 2025
Candel Therapeutics Inc (NASDAQ:CADL) has announced its inclusion in several value-oriented Russell indexes as part of the 2025 Russell US Indexes annual reconstitution. The changes became effective w
Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution
08:05am, Wednesday, 09'th Jul 2025
NEEDHAM, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Wednesday, 25'th Jun 2025
Candel Therapeutics (CADL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Candel Therapeutics announces $15M direct offering to support CAN-2409 launch preparations
10:02am, Tuesday, 24'th Jun 2025
Candel Therapeutics Inc (NASDAQ:CADL) has announced a $15 million registered direct offering of common stock, the proceeds of which will support launch readiness, medical affairs, and pre-commercializ
Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
09:05am, Tuesday, 24'th Jun 2025
NEEDHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic
Candel Therapeutics names Charles Schoch as CFO after interim tenure
09:39am, Monday, 23'rd Jun 2025
Candel Therapeutics Inc (NASDAQ:CADL) announced that it has appointed Charles Schoch as its chief financial officer. Schoch had served as interim CFO since January 2024 and is being elevated to the pe
Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer
08:05am, Monday, 23'rd Jun 2025
Interim CFO elevated to permanent role after demonstrating exceptional financial leadership, guiding the company through major operational and financial milestones Interim CFO elevated to permanent ro
Candel Therapeutics adds biotech veteran Maha Radhakrishnan to Board
08:33am, Friday, 06'th Jun 2025
Candel Therapeutics Inc (NASDAQ:CADL) has appointed biotechnology industry veteran Maha Radhakrishnan, M.D., to its board of directors.
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
08:05am, Friday, 06'th Jun 2025
Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development Appointment of sea
Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?
11:01am, Monday, 02'nd Jun 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 285.3% in Candel Therapeutics (CADL). While the effectiveness of this highly sought-after metric is questionabl
